The phosphoinositide 3-kinase (PI3K) pathway has a crucial role in tumor progression and drug resistance, including both conventional chemotherapeutics as well as novel agents. 1 Although no mutations have been described in the PI3K/Akt genes in multiple myeloma (MM), it was shown that this pathway is constitutively activated in MM cells and has pleiotropic effects influencing proliferation, drug resistance, angiogenesis and cell adhesion. PI3Ks are divided into three subclasses, and of these, class I PI3Ks-p110a (also known as PIK3CA), p110b (also known as PIK3CB), p110g (also known as PIK3CG) and p110d (also known as PIK3CD)-are well described in terms of their role in cancer development and progression. 1, 3 PIK3CA is frequently mutated in solid tumors including carcinoma of the prostate, breast colon and endometrium. 4, 5 However, there have been no reports of cancerspecific mutations in MM. 6 Recently, a number of potential therapeutics targeting specific PI3K groups or isoforms were developed. 3, 4 Previous studies have indicated that p110a, p110b and p110d might be potential targets for MM. [7] [8] [9] Although the basic framework of PI3K signaling has been uncovered, the contribution of the different PI3K isoforms is not well understood. 4 In the current study, we investigated the functional role of class I PI3K isoforms in modulating MM cell trafficking in vivo and in vitro.
To examine activation of the PI3K/Akt pathway in MM, we first performed gene set enrichment analysis 10 on the gene-expression data set (Shaughnessy et al. ref. GSE24080) of patients in different International Staging System stages of MM compared with normal donors; 11 and found enrichment of genes related to class I PI3K-activated AKT signaling events. These findings were observed in stage I, II and III MM patients compared with healthy individuals (Figure 1a) .
To study the role of each isoform (p110a, b, g, and d) in regulating MM cell survival and trafficking in vivo and in vitro, the expression of PI3K isoforms was examined in a panel of eight MM cell lines showing different levels of expression of PI3K isoforms with only MM.1S expressing all isoforms (Figure 1b) . Thus, MM.1S-GFP þ /luc þ was infected with lentivirus-mediated small hairpin RNAs targeting the different PI3K isoforms. Stable cell lines were generated, and efficiency of knockdown for each isoform was confirmed by reverse transcription quantitative PCR (Figure 1c) . Specificity of knockdown was demonstrated by immunoblotting in cell lines using specific antibodies against each isoform (Figure 1d ). Then, we evaluated the effect of each isoform on PI3K-Akt signaling in MM cells in the context of primary MM bone marrow mesenchymal stromal cells (BM-MSCs) and found inhibition of BM-MSC-dependent induction of phospho(p)-Akt in MM cells with all PI3K isoforms silenced in the tumor clone ( Figure 1e ). Although p110a, b, and d showed a modest reduction in cell survival in vitro (Figure 1f ), cell cycle analysis revealed no significant difference on cell cycle distribution patterns (Supplementary Figure 1) . We next performed adhesion assay of MM cells to primary MM-derived BM-MSCs; and found that by silencing each of class I PI3K isoforms, MM cells inhibited their adhesion properties, with the p110b and p110d knockdown being the most effective (53% reduction and 47% reduction, respectively; Po0.001, Po0.01; Figure 1g ).
To test the effect of the different p110 isoforms on MM tumor progression in vivo, SCID-Bg mice were injected with MM cells silenced for p110a, b, g and d, and tumor development was monitored by bioluminescence imaging. Scramble-infected cells were used as control. In consistent with in vitro data demonstrating that the most significant changes were observed for adhesion of MM cells to BM-MSCs in p110b and p110d knockdown cells, tumor progression was significantly lower in p110b-and p110d-knockdown cell-injected mice compared with scramble cell-injected mice (Po0.05); whereas tumor growth observed in p110a-and p110g-knockdown cell-injected mice was similar to control mice (Figures 2a and b) . We speculate that this might be due to markedly decreased tumor cell growth triggered by MM cell adhesion to BM-MSCs, as the adhesion of MM cells to BM-MSCs activates many pathways and has a vital role in MM pathogenesis and disease progression. 12 We further confirmed that tumor cells showed knockdown for each p110 isoform, as demonstrated ex vivo on tumor cells harvested from each cohort of mice (Figure 2c ). Mice were followed until the development of hind limb paralysis or death, and Kaplan-Meier analysis was performed showing prolonged survival in all groups except p110a mice (p110b and p110g, Po0.05; p110d, Po0.001; Figure 2d ). Despite similar tumor burden observed between p110g mice and scramble control-injected mice, mice injected with p110g knockdown cells had improved survival compared with control mice. This might be due to the different extent of tumor involvement of various organs 13 between the two groups, thus explaining the differences in survival.
Interestingly, our data indicate that p110a is not critical for the survival of MM cells in vivo. Unlike most solid tumor malignancies, where PI3KCA (p110a) mutation is the leading cause of activation of this pathway and is the target of many therapeutic agents in development, 3 there have been no reports of this specific mutations in MM. 6 Moreover, it was shown that unlike wild-type p110a, overexpression of the wild-type p110b, p110g and p110d is sufficient to induce an oncogenic transformation of fibroblasts in cell culture. 14 In this study, p110b was highly expressed in all MM cell lines, whereas only a minor subset expressed p110d at the protein level (Figure 1b) , which is consistent with a recent report 9 showing expression of p110b in 38 MM cell lines in comparison to the detectable expression of p110d in only 4 cell lines. In addition, another study 8 reported similar findings in cell lines showing lack of p110d expression in most MM cell lines. Of note, we found discrepancies in p110d expression in cell lines between our study and prior published studies but our data was confirmed in the Cancer Cell Line Encyclopedia data at the mRNA level (data not shown). 15 Importantly, Ikeda et al. 8 evaluated p110d levels in patient samples and detected its expression in all 24 MM patients. This may provide a clinical rationale for targeting p110d despite the lack of expression of p110d in MM cell lines.
Overall, our data suggest that, in contrast with solid tumors, MM may be more dependent on PI3K p110b and p110d and less dependent on PI3Ka, and these may be the focus of drug development in this hematological malignancy. were cocultured with BMSCs overnight, and MM cells were then separated from the BMSCs, lysed and whole-cell lysates were subjected to immunoblotting (e) with Akt and P-Akt (Thr308 and Ser473), which shows decreased phosphorylation of Akt in knockdown cells. The effects of inhibition of PI3K isoforms by shRNAs on cell survival were assessed by 3-(4,5-dimethylthiazol-2-yl)2-2-diphenyltetrazolium bromide (MTT) assay (f ). Adhesion assay (g) was performed to show the ability of knockdown cells to adhere to BMSCs after 2 h of incubation.
